A "Living Medicine" Hidden in Frog Intestines

The Japanese tree frog, a small green amphibian commonly found in rice paddies and gardens across Japan, may hold the key to revolutionizing cancer treatment.

A research team led by Professor Eijiro Miyako at the Japan Advanced Institute of Science and Technology (JAIST) has demonstrated that a bacterium called Ewingella americana, isolated from the intestines of Japanese tree frogs, can completely eliminate colorectal cancer in mice with just a single injection. This groundbreaking research was published in the international journal Gut Microbes on December 10, 2025.

Why Amphibians Caught Scientists' Attention

Have you ever heard of a frog or lizard getting cancer? Probably not. This isn't simply because we don't observe these animals closely enough. In fact, biologists have long noted that spontaneous tumors are remarkably rare in wild amphibians, a mystery that has puzzled scientists for years.

With recent advances revealing the profound influence of gut bacteria on immune function and cancer progression, the research team hypothesized that the unique gut microbiome of amphibians might harbor cancer-fighting secrets.

Finding a "Super Bacterium" Among 45 Strains

The research team collected gut bacteria from three species of amphibians and reptiles native to Japan. Their subjects included the Japanese tree frog (Dryophytes japonicus), the Japanese fire belly newt (Cynops pyrrhogaster), and the Japanese grass lizard (Takydromus tachydromoides).

From these animals, they isolated a total of 45 bacterial strains and systematically screened them for safety and antitumor effects. Nine strains showed antitumor activity, but one stood out dramatically: Ewingella americana from the Japanese tree frog.

Achieving an Unprecedented 100% Complete Response Rate

In a mouse colorectal cancer model, a single intravenous administration of E. americana achieved complete tumor elimination with a 100% complete response (CR) rate. This dramatically surpasses the efficacy of current standard treatments, including immune checkpoint inhibitors (anti-PD-L1 antibody) and chemotherapy agents (liposomal doxorubicin).

In comparative trials, chemotherapy and immunotherapy showed only partial effectiveness in some mice. In contrast, every single mouse in the bacterial treatment group saw their tumors completely disappear.

Even more remarkable was the durability of this cure. When researchers attempted to re-implant cancer cells into the cured mice 30 days later, the tumors failed to grow. This suggests that the bacterial treatment had effectively "vaccinated" the mice, generating an immunological memory that rejected cancer upon recurrence.

A Dual-Action Attack Mechanism

The exceptional anticancer effect of E. americana stems from its unique two-pronged attack mechanism.

Direct Cytotoxic Effect

This bacterium is a facultative anaerobe: it can survive in oxygen but thrives in low-oxygen environments. The core of solid tumors is typically hypoxic, creating a fortress that many anticancer drugs struggle to penetrate. For E. americana, however, this oxygen-starved environment is the perfect habitat.

Within 24 hours of administration, bacterial counts within tumors increased approximately 3,000-fold. This explosive growth enables direct destruction of cancer cells.

Immune Activation Effect

The bacterial presence powerfully stimulates the immune system, recruiting T cells, B cells, and neutrophils to the tumor site. These immune cells produce pro-inflammatory cytokines (TNF-α, IFN-γ) that further amplify immune responses and induce cancer cell apoptosis.

This combination of "direct attack" and "immune activation" produces effects that far exceed conventional treatments.

Precision Targeting: Tumors Only

Perhaps the most remarkable feature of this bacterium is its extraordinary tumor specificity. E. americana selectively accumulates in tumor tissues while showing zero colonization in normal organs.

This selectivity arises from multiple factors unique to the tumor environment. The hypoxic conditions inside tumors promote anaerobic bacterial proliferation. Cancer cells express CD47 protein, creating local immunosuppression that forms a permissive niche for bacterial survival. The abnormal, leaky blood vessels in tumor tissue facilitate bacterial entry. Additionally, tumor-specific metabolites support selective bacterial growth.

An Excellent Safety Profile

Comprehensive safety evaluation revealed impressive results. Regarding blood clearance, the bacterium has a half-life of approximately 1.2 hours and becomes completely undetectable within 24 hours. For normal organ effects, zero bacterial colonization was found in the liver, spleen, lungs, kidneys, or heart. The inflammatory response was only transient and mild, normalizing within 72 hours. Long-term observation over 60 days showed no chronic toxicity.

Importantly, the bacterium is sensitive to standard antibiotics, providing a safety "kill switch" if any problems arise during treatment.

Future Prospects and Challenges

This research has established proof-of-concept for a novel cancer therapy using natural bacteria. The research team plans to pursue several avenues. For expansion to other cancer types, they will validate efficacy in breast cancer, pancreatic cancer, melanoma, and other malignancies. For optimization of administration methods, they will develop safer and more effective delivery approaches, including dose fractionation and intratumoral injection. For combination therapy development, they will investigate synergistic effects with existing immunotherapy and chemotherapy.

However, it's crucial to note that these results were obtained in mouse models. Translation to human applications will require further research, including additional safety confirmation, determination of appropriate dosing, and detailed mechanistic studies of how the bacteria reach and attack tumors.

Biodiversity: A Treasury of Medical Innovation

Professor Miyako stated, "This research demonstrates that unexplored biodiversity represents a treasure trove for new medical technology development, while potentially providing new treatment options for patients with refractory cancers."

The discovery that a common frog's gut harbors potential weapons against one of humanity's deadliest diseases reminds us that nature still holds countless medical treasures waiting to be discovered.

What about your country? Is research on gut bacteria or microbiome-based cancer treatments advancing? Have there been any discoveries of medical applications from common animals in your region? We'd love to hear your thoughts!

References